Anna M Acosta1, Chas DeBolt2, Azadeh Tasslimi2, Melissa Lewis3, Laurie K Stewart2, Lara K Misegades4, Nancy E Messonnier4, Thomas A Clark4, Stacey W Martin4, Manisha Patel4. 1. Epidemic Intelligence Service, Scientific Education and Professional Development Program Office, Meningitis and Vaccine Preventable Disease Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, and amacosta@cdc.gov. 2. Communicable Disease Epidemiology, Washington State Department of Health, Shoreline, Washington. 3. Biostatistics Office, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and. 4. Meningitis and Vaccine Preventable Disease Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, and.
Abstract
BACKGROUND: Acellular pertussis vaccines replaced whole-cell vaccines for the 5-dose childhood vaccination series in 1997. A sixth dose of pertussis-containing vaccine, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap), was recommended in 2005 for adolescents and adults. Studies examining Tdap vaccine effectiveness (VE) among adolescents who have received all acellular vaccines are limited. METHODS: To assess Tdap VE and duration of protection, we conducted a matched case-control study during the 2012 pertussis epidemic in Washington among adolescents born during 1993-2000. All pertussis cases reported from January 1 through June 30, 2012, in 7 counties were included; 3 controls were matched by primary provider clinic and birth year to each case. Vaccination histories were obtained through medical records, the state immunization registry, and parent interviews. Participants were classified by type of pertussis vaccine received on the basis of birth year: a mix of whole-cell and acellular vaccines (1993-1997) or all acellular vaccines (1998-2000). We used conditional logistic regression to calculate odds ratios comparing Tdap receipt between cases and controls. RESULTS: Among adolescents who received all acellular vaccines (450 cases, 1246 controls), overall Tdap VE was 63.9% (95% confidence interval [CI]: 50% to 74%). VE within 1 year of vaccination was 73% (95% CI: 60% to 82%). At 2 to 4 years postvaccination, VE declined to 34% (95% CI: -0.03% to 58%). CONCLUSIONS: Tdap protection wanes within 2 to 4 years. Lack of long-term protection after vaccination is likely contributing to increases in pertussis among adolescents.
BACKGROUND: Acellular pertussis vaccines replaced whole-cell vaccines for the 5-dose childhood vaccination series in 1997. A sixth dose of pertussis-containing vaccine, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap), was recommended in 2005 for adolescents and adults. Studies examining Tdap vaccine effectiveness (VE) among adolescents who have received all acellular vaccines are limited. METHODS: To assess Tdap VE and duration of protection, we conducted a matched case-control study during the 2012 pertussis epidemic in Washington among adolescents born during 1993-2000. All pertussis cases reported from January 1 through June 30, 2012, in 7 counties were included; 3 controls were matched by primary provider clinic and birth year to each case. Vaccination histories were obtained through medical records, the state immunization registry, and parent interviews. Participants were classified by type of pertussis vaccine received on the basis of birth year: a mix of whole-cell and acellular vaccines (1993-1997) or all acellular vaccines (1998-2000). We used conditional logistic regression to calculate odds ratios comparing Tdap receipt between cases and controls. RESULTS: Among adolescents who received all acellular vaccines (450 cases, 1246 controls), overall Tdap VE was 63.9% (95% confidence interval [CI]: 50% to 74%). VE within 1 year of vaccination was 73% (95% CI: 60% to 82%). At 2 to 4 years postvaccination, VE declined to 34% (95% CI: -0.03% to 58%). CONCLUSIONS:Tdap protection wanes within 2 to 4 years. Lack of long-term protection after vaccination is likely contributing to increases in pertussis among adolescents.
Authors: Sara Y Tartof; Melissa Lewis; Cynthia Kenyon; Karen White; Andrew Osborn; Juventila Liko; Elizabeth Zell; Stacey Martin; Nancy E Messonnier; Thomas A Clark; Tami H Skoff Journal: Pediatrics Date: 2013-03-11 Impact factor: 7.124
Authors: Joel I Ward; James D Cherry; Swei-Ju Chang; Susan Partridge; Hang Lee; John Treanor; David P Greenberg; Wendy Keitel; Stephen Barenkamp; David I Bernstein; Robert Edelman; Kathryn Edwards Journal: N Engl J Med Date: 2005-10-13 Impact factor: 91.245
Authors: Karen R Broder; Margaret M Cortese; John K Iskander; Katrina Kretsinger; Barbara A Slade; Kristin H Brown; Christina M Mijalski; Tejpratap Tiwari; Emily J Weston; Amanda C Cohn; Pamela U Srivastava; John S Moran; Benjamin Schwartz; Trudy V Murphy Journal: MMWR Recomm Rep Date: 2006-03-24
Authors: Douglas J Opel; Matthew P Kronman; Douglas S Diekema; Edgar K Marcuse; Jeffrey S Duchin; Eric Kodish Journal: Pediatrics Date: 2016-03-18 Impact factor: 7.124
Authors: Freddy Caldera; Sumona Saha; Arnold Wald; Christine A Garmoe; Sue McCrone; Bryant Megna; Dana Ley; Mark Reichelderfer; Mary S Hayney Journal: Dig Dis Sci Date: 2018-03-29 Impact factor: 3.199